SCHEMBL5364288

SCHEMBL5364288

CC(COc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1)NCS(C)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
ABCB1 P08183 1/20 0.44
PTPN11 Q06124 1/20 0.42
EED O75530 1/20 0.41
ACHE P22303 1/20 0.41
MC4R P32245 1/20 0.41
GAA P10253 2/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
GPR119 Q8TDV5 2/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
DRD2 P14416 1/20 0.40
HCRTR1 O43613 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374555 0.88 L3MBTL1 (0.47) L3MBTL1ABCB1EEDACHEGAA
SCHEMBL14570987 0.88 L3MBTL1 (0.47) L3MBTL1ABCB1EEDACHEGAA
SCHEMBL5338019 0.83 L3MBTL1 (0.57) L3MBTL1ABCB1ACHEGAAKMT2A
SCHEMBL5364295 0.81 L3MBTL1 (0.46) L3MBTL1ABCB1EEDMC4RKMT2A
SCHEMBL5382307 0.81 L3MBTL1 (0.52) L3MBTL1ABCB1ACHEGAAKMT2A
SCHEMBL5371729 0.79 L3MBTL1 (0.52) L3MBTL1ABCB1ACHEMC4RGAA
SCHEMBL5374194 0.78 BACE1 (0.56) L3MBTL1ABCB1ACHEKMT2A
SCHEMBL14570822 0.78 L3MBTL1 (0.48) L3MBTL1ABCB1EEDACHEPKM
SCHEMBL5374340 0.78 L3MBTL1 (0.48) L3MBTL1ABCB1EEDACHEPKM
SCHEMBL5362572 0.78 SMARCA2 (0.45) L3MBTL1EEDACHEGAAGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186715-B2 Piperazine- and piperidine-derivatives as melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-03-06 US disclosed
EP-1370558-B1 PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-24 EP disclosed
US-20040082590-A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists ELI LILLY AND COMPANY 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082590-A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists MC1R, MC4R, MC5R L3MBTL1 4593/4885ABCB1 3389/4885PTPN11 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.